Loading...
Derniers dépôts
-
Medhi Hassani, Dylan Moutachi, Mégane Lemaitre, Alexis Boulinguiez, Denis Furling, et al.. Beneficial effects of resistance training on both mild and severe mouse dystrophic muscle function as a preclinical option for Duchenne muscular dystrophy. PLoS ONE, 2024, 19, ⟨10.1371/journal.pone.0295700⟩. ⟨hal-04501283⟩
-
Pierre Joanne, Yeranuhi Hovhannisyan, Alexandre Simon, Gaëlle Revet, Romain Diot, et al.. Generation of human induced pluripotent stem cell lines from five patients with Myofibrillar myopathy carrying different heterozygous mutations in the DES gene. Stem Cell Research, 2024, 76, pp.103338. ⟨10.1016/j.scr.2024.103338⟩. ⟨hal-04466294⟩
-
Pascal Laforêt, Michio Inoue, Evelyne Goillot, Claire Lefeuvre, Umut Cagin, et al.. Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. Acta Neuropathologica Communications, 2019, 7 (1), ⟨10.1186/s40478-019-0815-2⟩. ⟨hal-02414161⟩
-
Florence Boisgérault, Amine Meliani, Romain Hardet, Solenne Marmier, Fanny Collaud, et al.. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nature Communications, 2018, 9 (1), pp.4098. ⟨10.1038/s41467-018-06621-3⟩. ⟨hal-02177709⟩
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
Lidia Almenara-Fuentes, Silvia Rodriguez-Fernandez, Estela Rosell-Mases, Katerina Kachler, Axel You, et al.. A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens. Nanomedicine: Nanotechnology, Biology and Medicine, 2023, pp.102635. ⟨10.1016/j.nano.2022.102635⟩. ⟨hal-03885962⟩
-
Florent Porquet, Lin Weidong, Kévin Jehasse, Hélène Gazon, Maria Kondili, et al.. Specific DMPK-promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells. Molecular Therapy - Nucleic Acids, 2023, 32, pp.857 - 871. ⟨10.1016/j.omtn.2023.05.007⟩. ⟨hal-04287597⟩
Nombre de documents
770
Nombre de notices
1 375
widget_cloud
Thérapie génique
Lamin A/C
Actin
Cytoskeleton
Male
Astrocyte
Neuromuscular disease
Fabry disease
Animals
Satellite cells
Neuromuscular diseases
Heart failure
Myotonic dystrophy
Autophagy
LMNA
Clinical trials
Diagnosis
Satellite cell
Neuromuscular junction
CMS
Myotonic Dystrophy type 1
FSHD
Transgenic mouse model
Dilated cardiomyopathy
DMD
LMNA gene
Laminopathies
Myogenesis
Cytokines
Autoimmune diseases
Biomarkers
Centronuclear myopathy
PABPN1
Exercise
RNA interference
Cardiomyopathy
Dystrophin
Long read sequencing
AAV
Cell therapy
Inflammation
Autoimmunity
Therapy
Laminopathy
Heart
Skeletal muscle
Aged
Dermatomyositis
ALS
Rare neuromuscular diseases
Myasthenia Gravis MG
Muscle
Regeneration
Becker muscular dystrophy
Congenital myopathy
Calcium
Myotonic dystrophy type 1
Duchenne muscular dystrophy
Gene therapy
Muscular dystrophy
Cancer
CRISPRi
Antisense oligonucleotides
Motoneuron
Transcriptomics
Myasthenia gravis
Treatment
Myopathies
Errance diagnostique
COVID-19
Myoblasts
Glutamate
Mouse model
Rare diseases
Biomarker
Trinucleotide repeat expansion
Lamin A/C LMNA gene
CTG repeat contractions
RNA biology
Outcome measures
OPMD
Thymus
Autoantibodies
Brain
MBNL
Myotonic Dystrophy
Myositis
Muscle regeneration
Humans
Congenital muscular dystrophy
Fibrosis
Genotype phenotype correlation
Mechanotransduction
Laminopathie
Nuclear envelope
Myopathy
Dynamin 2
Aging
Alternative splicing
Amyotrophic lateral sclerosis